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Abstract 
This letter comments on the article “The treatment of sarcoptic mange in wildlife: a systematic review” published in 
Parasites & Vectors 2019, 12:99, and discusses the limitations in the use of endectocides for scabies control in free‑
ranging wildlife. The ecological impact and drug resistance to ivermectin are also discussed. In our view, scabies 
control in free‑ranging wildlife should be based preferably on population management measures, and whether to 
apply individual treatments to free‑ranging populations should be considered very carefully and avoided where not 
absolutely warranted.
Keywords: Sarcoptes scabiei, Wildlife diseases, Ivermectin, Drug resistance, Soil pollution
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Letter to the Editor
Recently, Rowe and colleagues have published an inter-
esting review of the treatment of sarcoptic mange (here-
after “scabies”) in wildlife [1]. This review highlighted the 
impact of this worldwide distributed parasitic disease 
and pointed out the need for consensus in the implemen-
tation of effective treatment of captive and free-ranging 
wildlife affected by scabies.
Although we fully agree on the need for a conven-
tion on scabies control in wildlife, we would like to draw 
attention to the challenges and risks of implementing 
protocols based on pharmacological treatments in the 
wild. In this letter, we will set out some reasons for the 
incongruency of such drug-based approach.
After the systematic review of 2205 publications, 
Rowe et  al. [1] kept 28 relevant articles reporting phar-
macological effective treatments of scabies in wildlife, 
notably ivermectin delivered multiple times via subcu-
taneous injection. Most of these studies share a clinical 
treatment approach rather than population-based disease 
management.
Since the availability of ivermectin formulations for 
animal use in 1975, this drug became the most effec-
tive and safe treatment for a broad range of endo- and 
ectoparasites including Sarcoptes scabiei [2–4]. In fact, 
ivermectin is included amongst the election drugs to 
treat scabies not only in humans [5, 6] but also in domes-
tic [7] and wild mammals [8]. This macrocyclic lactone 
is mainly delivered orally (e.g. in the form of drenching), 
pour-on or subcutaneously [2, 7] in physical or chemical 
restrained individuals. Based on our professional experi-
ences and field research using ivermectin and drugs with 
related treatment regime methods, ivermectin treat-
ments may be feasible for target individuals but highly 
challenging to unrealistic for whole populations in most 
instances.
Most of the studies reviewed by Rowe et  al. [1] were 
focused on captive wildlife and only six out of the 28 
papers were supposed to describe the output of ivermec-
tin to control mange in free-ranging wildlife. Neverthe-
less, and after a careful reading of these articles, we noted 
that none of them was about the use of ivermectin to 
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populations. For example, the studies of Skerratt et al. [9] 
and Ruykys et  al. [10] were largely conducted on wom-
bats (Vombatus ursinus and Lasiorhinus latifrons, respec-
tively) kept in captivity until their recovery. On the other 
hand, Kalema-Zikusoka et  al. [11] worked with a group 
of four free-ranging gorillas (Gorilla beringei) habitu-
ated to human presence which facilitated their approach 
and treatment. Similarly, Chhangani et  al. [12], treated 
a troop of Hanuman langurs (Semnopithecus entellus) 
living close to human habitations and religious places. 
Expanding urbanization and habitat loss, are leading to 
increasingly common human-wildlife interfaces [13], and 
as a result, much of the free-ranging wildlife identified as 
suffering from sarcoptic mange and becoming candidates 
for treatment might be habituated to humans to varying 
degrees.
Rajkovic-Janje et al. [14] focused on the use of ivermec-
tin for endoparasite control in the wild boar. Sarcoptic 
mange was detected only in skin samples collected after 
the necropsy of four piglets. Moreover, sarcoptic mange 
can occur subclinically in this species [15] and others, 
and therefore the lack of clinical signs after the ivermec-
tin treatment is not always a reliable indicator of recov-
ery. Gakuya et  al. [16], however, showed the outcomes 
of successful ivermectin treatment of endemic scabies 
in Thomson’s gazelles (Eudorcas thomsonii) and chee-
tahs (Acinonyx jubatus) from the Masai Mara National 
Park. The peak of scabies prevalence here ranged from 
7.4% (n = 10 scabietic gazelles) to 28% (n = 2 scabietic 
cheetahs) affecting a small number of individuals that 
were captured and ear-tagged for potential re-treatment. 
Even though that work was representing an outbreak in 
free-ranging wildlife, the numbers of affected individuals 
are far from those recorded during scabies outbreaks in 
European fauna, e.g. the Northern chamois (Rupicapra 
rupicapra; n = 1696 affected individuals, 16.6% of the 
chamois population [17, 18]), or the Iberian ibex (Capra 
pyrenaica; c.7695 scabietic individuals, 80% of the ibex 
population in Sierra de Cazorla [19] and 3382 scabietic 
individuals, 23% of Sierra Nevada ibex population [20]).
Pharmacological treatment of mange in wild animals 
mostly produces individual healing, but its effects on 
achieving control or eradication in a population are 
mostly inconclusive [21]. Therefore, gathering more 
information on the population and environmental 
effects and on the consequences of massive antipara-
sitic treatments has been recently recommended, 
approaching the management of sarcoptic mange in 
wildlife populations from a wider ecological perspec-
tive [22]. As opposed to the individual approach revised 
by Rowe et  al. [1], the success of scabies control in 
free-ranging wildlife depends on the size of the tar-
get population, scabies prevalence, and the feasibility 
of reaching the required percentage of the population 
with any specific treatment or measure [23]. Individual-
ized pharmacological therapies, however, are desirable 
for vulnerable or endangered species where the com-
plete recovery of specific individuals is decisive for spe-
cies recovering (e.g. see an example for the Iberian lynx, 
Lynx pardinus [24], or for the black bear, Ursus ameri-
canus [25]). However, in abundant non-threatened and 
widespread populations with a high prevalence of sca-
bies, it is unlikely that any individual approach would 
reach the necessary proportion of the population to 
prevent transmission and reinfection. This is even 
more evident for ivermectin due to the need for mul-
tiple doses to achieve a complete recovery and the total 
elimination of all mites from the host and the environ-
ment, although other long-acting drugs could be a bet-
ter option. Nevertheless, the environmental and public 
health concerns of massive antiparasitic drug release in 
the environment would still persist [23].
While of recognized limited efficacy, selective culling 
of clinically affected individuals is also a common strat-
egy in epizootic outbreak scenarios in free-ranging wild-
life [26]. However, this population management measure 
is not free of disadvantages, such as the culling of indi-
viduals recovering from scabies [27] in detriment of the 
host population viability, as well as the possible objec-
tions from the public opinion in some particular species 
considered national icon, such as koalas (Phascolarctos 
cinereus) and wombats in Australia.
It is also important to acknowledge the potential for 
non-target environmental effects of mass administra-
tion of ivermectin. Avermectins are excreted during four 
days post-treatment and it can be detected in feces for 
up to 40 days post-defecation [28] and for more than one 
year in reindeer pastures [29]. In soil, ivermectin shows 
a half-life degradation between 7 and 217 days, depend-
ing on the solar radiation [3]. Once on the environment, 
this drug has pre-lethal consequences for dung beetles 
[30] and for other dung-dwelling invertebrates [3]. If the 
drug is delivered orally in feeding stuff, as per common 
practice in game ungulate populations in Spain, soil con-
tamination and thus the potential effects of ivermectin 
on other terrestrial fauna, and possibly food chain effects, 
could be expected not only through fecal contamination 
but through the drug preparation itself. On the other 
hand, game treatment would limit venison consump-
tion, as ivermectin withdrawal time in edible tissues may 
vary from 18 to 48 days depending on the administration 
route [7, 23, 31]. Finally, another concern about the use 
of ivermectin for scabies control in wildlife is the drug 
resistance phenomenon recently described in human sca-
bies [32, 33] and also suspected in companion animals 
[34].
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In line with Rowe et al. [1], little is known about the 
outcome of pharmacological mass treatments of scabies 
outbreaks in free-ranging wildlife populations. Previ-
ous reports and our own experience after decades of 
scabies investigation in mountain ungulates unveil that 
no strategy has ever unambiguously resulted in effec-
tive control of scabies in naive or endemically affected 
herds [23]. Instead, initial outbreak epizootics can 
become enzootic in successive waves as mite and host 
mutually adapt [35, 36]. We should also acknowledge 
that a range of environmental, host and pathogen fac-
tors can influence disease dynamics between enzootic, 
epizootic and disease-free scenarios [37]. Accordingly, 
whether to apply individual treatments to free-ranging 
populations should be considered very carefully and 
avoided when not absolutely warranted.
Bearing in mind the points provided here, we advo-
cate for careful consideration of the potential limita-
tions of the pharmacological treatment of free-ranging 
wildlife before the use of endectocide drugs in sca-
bies outbreaks, considering: feasibility and efficacy, 
ecological impact, drug resistance, drug residues in 
meat  (for animal and human consumption) and eco-
nomics, among others. Balancing the relative merits of 
traditional ecological population-based management 
approaches to handle scabies outbreaks independent 
of drug-based treatments may be warranted in many 
free-ranging wildlife contexts. Similarly, a pragmatic 
assessment of whether the control can be achieved, and 
intervention therefore justified, should always be made.
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